Best oral presenter Dr. Olga Salamero chosen as the tomy’s winner.
Research focused on treatments in elderly APL patients
AMSTERDAM--(BUSINESS WIRE)--Oct. 5, 2017--
Teva Pharmaceuticals Europe BV, (NYSE and TASE: TEVA) announced the
winner of the tomy’s (Teva’s Orphan hematological Malignancies award for
Young hematologists) at the 7th International Symposium on
Acute Promyelocytic Leukemia (APL) in Rome, Italy last week. During the
event entitled, ‘Next-Generation APL Leaders: Teva’s Award for Young
Hematologists’ Dr. Salamero was awarded a tomy’s trophy, as well as a
bursary to attend the 2017 American Society of Hematology (ASH) Annual
Meeting, taking place in the USA in December.
This press release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20171005005748/en/
Dr. Olga Salamero presenting her research during the Next-Generation APL Leaders Teva’s Award for Young Hematologists in Rome, Italy (Photo: Business Wire)
Dr. Salamero is currently a hematologist at the Vall d’Hebron University
Hospital, Barcelona, Spain and presented research entitled Very
elderly acute promyelocytic leukemia: a multicentric experience. The
study selected patients aged ≥ 75 years old with APL who had reported to
PETHEMA registry (Spanish Hematology Treatment Programme) over the last
nineteen years. Epidemiologic characteristics and disease features in
the very elderly APL population were analysed and the percentage of
patients treated according to investigators criteria described. The
research found that patients treated with all-trans retinoic acid (ATRA)
plus anthracycline-based regimen showed better outcomes than patients
who received other strategies, such as ATRA alone, chemotherapy alone or
best supportive care.
Speaking after the awards ceremony, Dr. Salamero said, “Winning the
tomy’s - it’s been a pleasure. I feel proud, not because of my work but
the work of the PETHEMA group. I would recommend attending the APL
Symposium as not only is it very interesting, but it facilitates a lot
and keeps you in touch with your peers.”
The tomy’s are an educational award programme for young hematologists,
sponsored by Teva Oncology. The awards are open to young hematologists,
or young physicians training to become hematologists aged 40 years or
younger. The entrants are challenged to illustrate the latest scientific
advancements in the management of orphan hematological malignancies by
presenting a case study or case series demonstrating their excellence in
education and presentation skills. The independent jury for the 2017
tomy’s was comprised of experts in orphan hematological malignancies and
includes Pierre Fenaux, France; Richard Schlenk, Germany; Francesco
Lo-Coco, Italy; Bob Löwenberg, Netherlands; Nigel Russell, UK and Miguel
Sanz, Spain.
“It’s estimated that between 1,500 – 2,000 people in Europe are
diagnosed with APL each year. Even though APL is the most lethal type of
acute leukemia, it’s highly curable and more research into this disorder
is urgently needed. The tomy’s programme reflects Teva’s commitment to
encouraging new and innovative research aimed at improving patient
outcomes in orphan hematological malignancies,” said Paul Harmon, Head
of Teva’s Oncology Care and Transplant Europe.
“APL can cause a number of symptoms including uncontrollable bleeding
and can kill within hours or days if left untreated. As it’s so rare,
APL can be difficult to recognise and diagnose. We’re excited about this
programme, and we believe it will stimulate new exciting research, with
the ultimate ambition of saving lives,” commented Prof. Lo-Coco, tomy
jury member.
The full list of finalists as well as more information on the jury can
be accessed via: https://www.thinkapl.com/jury/
The tomy’s awards ceremony in Rome follows the inaugural tomy’s awards,
announced at the Teva Oncology Satellite Symposium at the Acute
Leukemias XVI International Symposium, which took place in Munich,
Germany, in February 2017.
For more information on the Tomy’s awards or for queries regarding
abstract submissions or notifications, please contact: support@oncotomys.com.
-ENDS-
About Teva
Teva is among the top 15 global pharmaceutical companies globally,
delivering high-quality, patient-centric healthcare solutions used by
approximately 200 million patients in 60 markets every day. Teva
produces a leading innovative treatment for multiple sclerosis and has
late-stage development programs for a range of disorders of the central
nervous system, including movement disorders, migraine, pain and
neurodegenerative conditions. With its European headquarters in
Amsterdam, the Netherlands, Teva is the world’s largest generic
medicines producer, leveraging its portfolio of more than 1,800
molecules to produce a broad range of products in nearly every
therapeutic area. Teva draws on its specialty and generics capabilities
to seek new ways of addressing unmet patient needs by combining drug
development with devices, services and technologies. Teva's net revenues
in 2016 were $21.9 billion. For more information, visit www.tevapharm.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171005005748/en/
Source: Teva
Teva
Fiona Cohen
+31 6 2008 2545
or
Jayson
Otke
+31 6 8201 5407